文献速递真实世界研究与卫生经济医学人工智能与信息学流行病学与生物统计

中国基层医疗中移动健康赋能的分级糖尿病管理干预评估(ROADMAP):一项整群随机试验

Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial.
PubMed 文献 · PLoS Med · 2021-09-21

在中国25个省份864个社区开展整群随机对照试验,纳入19601例2型糖尿病注册患者,评估移动健康赋能的分级管理干预。干预组在12个月时HbA1c控制率绝对提高7.0%,复合ABC控制率绝对提高1.9%,低血糖事件与体重增加无组间差异。

要点

  • 移动健康赋能分级管理可显著改善基层2型糖尿病患者的HbA1c控制率。
  • 干预对复合ABC控制率有轻度但显著的改善。
  • 低血糖事件和体重增加在干预组与常规护理组间无差异。

核心结论

  • 移动健康赋能的分级糖尿病管理干预有效改善了基层糖尿病控制,并有可能推广至类似背景下的其他慢性病管理。

研究设计与样本

  • 社区整群随机对照试验,2017年6月至2019年7月在中国25个省份864个社区招募19601例注册2型糖尿病患者。
  • 576个社区(13037例)随机分配至干预组,288个社区(6509例)分配至常规护理组。
  • 干预以分级护理团队提供的移动健康服务包为核心,由每次结构化门诊就诊时的每月血糖监测启动。

主要发现

  • 1年随访后,17554例(89.8%)完成终点评估,基线HbA1c为7.87%(SD 1.92%),37.3%的患者HbA1c<7.0%。
  • 与常规护理相比,干预使HbA1c控制率绝对提高7.0%(95%CI 4.0%至10.0%),相对提高18.6%(RR 1.186,95%CI 1.105至1.267)。
  • 复合ABC控制率绝对提高1.9%(95%CI 0.5至3.5),相对提高21.8%(RR 1.218,95%CI 1.062至1.395)。
  • 低血糖事件和体重增加在两组间无差异。

关键数值与推荐

  • 主要结局为HbA1c<7.0%的控制率,在基线和12个月时评估。
  • 复合ABC控制定义为HbA1c<7.0%、血压<140/80 mm Hg和LDL-C<2.6 mmol/L。

临床怎么用

  • 在基层医疗中可考虑采用移动健康赋能的分级管理服务包以改善2型糖尿病患者的血糖控制。

局限性

  • 除HbA1c外,实验室检测未集中化。
  • 将研究结果外推至未在基层医疗系统注册的患者时应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glycemic control remains suboptimal in developing countries due to critical system deficiencies. An innovative mobile health (mHealth)-enabled hierarchical diabetes management intervention was introduced and evaluated in China with the purpose of achieving better control of type 2 diabetes in primary care. METHODS AND FINDINGS: A community-based cluster randomized controlled trial was conducted among registered patients with type 2 diabetes in primary care from June 2017 to July 2019. A total of 19,601 participants were recruited from 864 communities (clusters) across 25 provinces in China, and 19,546 completed baseline assessment. Moreover, 576 communities (13,037 participants) were centrally randomized to the intervention and 288 communities (6,509 participants) to usual care. The intervention was centered on a tiered care team-delivered mHealth-mediated service package, initiated by monthly blood glucose monitoring at each structured clinic visit. Capacity building and quarterly performance review strategies upheld the quality of delivered primary care. The primary outcome was control of glycated hemoglobin (HbA1c; <7.0%), assessed at baseline and 12 months. The secondary outcomes include the individual/combined control rates of blood glucose, blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C); changes in levels of HbA1c, BP, LDL-C, fasting blood glucose (FBG), and body weight; and episodes of hypoglycemia. Data were analyzed using intention-to-treat (ITT) generalized estimating equation (GEE) models, accounting for clustering and baseline values of the analyzed outcomes. After 1-year follow-up, 17,554 participants (89.8%) completed the end-of-study (EOS) assessment, with 45.1% of them from economically developed areas, 49.9% from urban areas, 60.5 (standard deviation [SD] 8.4) years of age, 41.2% male, 6.0 years of median diabetes duration, HbA1c level of 7.87% (SD 1.92%), and 37.3% with HbA1c <7.0% at baseline. Compared with usual care, the intervention led to an absolute improvement in the HbA1c control rate of 7.0% (95% confidence interval [CI] 4.0% to 10.0%) and a relative improvement of 18.6% (relative risk [RR] 1.186, 95% CI 1.105 to 1.267) and an absolute improvement in the composite ABC control (HbA1c <7.0%, BP <140/80 mm Hg, and LDL-C <2.6 mmol/L) rate of 1.9% (95% CI 0.5 to 3.5) and a relative improvement of 21.8% (RR 1.218, 95% CI 1.062 to 1.395). No difference was found on hypoglycemia episode and weight gain between groups. Study limitations include noncentralized laboratory tests except for HbA1c, and caution should be exercised when extrapolating the findings to patients not registered in primary care system. CONCLUSIONS: The mHealth-enabled hierarchical diabetes management intervention effectively improved diabetes control in primary care and has the potential to be transferred to other chronic conditions management in similar contexts. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR) IOC-17011325.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Jia W, Zhang P, Zhu D, et al. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial. PLoS Med. 2021. PMID: 34547030. doi:10.1371/journal.pmed.1003754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。